Has Kousay Alkourainy received payments from drug or device companies?

Yes. Drug and device makers reported $5,272 in general payments to Kousay Alkourainy across 217 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Kousay Alkourainy did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Kousay Alkourainy come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Kousay Alkourainy

Hematology & Oncology · Chula Vista, CANPI 1457361271

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,903 of the $5,272 with a category attached, or 74.0%. 47 manufacturers reported payments, led by Novartis at 34.7% of the total. Reporting peaked in 2019 at $3,287 and has fallen 98.2% since, to $59 in 2022.

$5,272in general payments, 2019–2025

Across 217 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$2K
Merck$369
E.r. Squibb & Sons, L.L.C.$306
AstraZeneca$174
Pfizer$164
Astellas Pharma US Inc$152
plus $2K from 41 others

What the payments were for

Food & beverage$3,90374%
Education$792%
Gifts$1,29024%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	38	$1,829
Merck	22	$369
E.r. Squibb & Sons, L.L.C.	15	$306
AstraZeneca	10	$174
Pfizer	10	$164
Astellas Pharma US Inc	7	$152
Johnson & Johnson	8	$136
Gilead(2 entities)	5	$106
Exelixis Inc.	5	$105
Amgen	5	$104
Seagen Inc.	6	$95
Teva Pharmaceuticals USA, Inc.	4	$93
Genentech USA, Inc.	4	$86
Takeda Pharmaceuticals U.S.A., Inc.	4	$86
Boehringer Ingelheim	5	$85
Bristol Myers Squibb	4	$82
AbbVie	3	$82
Aurobindo Pharma USA, Inc.	1	$74
Coherus Oncology, Inc.	3	$71
Lilly USA, LLC	4	$70
Rigel Pharmaceuticals, Inc.	4	$65
Clovis Oncology, Inc.	3	$62
Daiichi Sankyo Inc.	3	$62
Dova Pharmaceuticals	3	$61
Puma Biotechnology, Inc.	3	$57
Kyowa Kirin, Inc.	3	$56
Tolmar Pharmaceuticals, Inc.	3	$54
Sanofi	2	$48
Karyopharm Therapeutics Inc.	2	$41
Taiho Oncology, Inc.	2	$41
Incyte Corporation	2	$39
Shionogi Inc	2	$37
Blueprint Medicines Corporation	2	$37
Bayer	2	$36
Pharmacyclics LLC, An Abbvie Company	2	$36
Secura Bio, Inc.	4	$34
Tersera Therapeutics LLC	2	$28
Dendreon Pharmaceuticals LLC	1	$27
Verastem, Inc.	1	$25
Mylan Institutional Inc.	1	$24
AMAG Pharmaceuticals, Inc.	1	$23
Ipsen Biopharmaceuticals, Inc	1	$21
Beigene USA, Inc.	1	$20
Helsinn Therapeutics (U.S.), Inc.	1	$20
Otsuka America Pharmaceutical, Inc.	1	$18
Eisai Inc.	1	$17
Stemline Therapeutics Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,272 in reported general payments places this provider in the 55th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Other hematology & oncology in Chula Vista

Dennis SlamonLos Angeles$3.1M
Sandra HorningStanford$2.5M
Mohammadbagher ZiariCorona$2.5M
George YaghmourLos Angeles$1.9M
Robert VescioWest Hollywood$1.1M
Kevin KellyLos Angeles$894K
Johnny ChangEncino$884K
Nitin RohatgiSacramento$814K
Omid HamidSanta Monica$809K
Catherine CoombsOrange$786K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →